Main idea: MP-AzeFlu was superior to AZE in reducing moderate-to-severe seasonal allergic rhinitis symptoms, providing earlier and better symptom relief.
The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in Russian seasonal allergic rhinitis (SAR) patients.
Moderate-to-severe allergic rhinitis and rhinoconjunctivitis patients (n = 149; aged 18-65 years) were randomized to receive MP-AzeFlu (137/50 μg AZE/FP per spray) or AZE (137 μg/spray), both as 1 spray per nostril twice daily, in a multi-center, open-label, 14-day, parallel-group trial.
Results: When compared with AZE spray-treated patients, those treated with MP-AzeFlu experienced significantly greater reductions in rhinitis and conjunctivitis symptoms. Superior relief observed on day 2 with MP-AzeFlu versus AZE was sustained throughout the study. MP-AzeFlu-treated patients experienced a greater improvement in the quality of life than AZE-treated. MP-AzeFlu spray was well tolerated.